<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Metab Syndr</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Metab Syndr</journal-id><journal-title-group><journal-title>Diabetes &#x00026; Metabolic Syndrome</journal-title></journal-title-group><issn pub-type="ppub">1871-4021</issn><issn pub-type="epub">1878-0334</issn><publisher><publisher-name>Diabetes India. Published by Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">S1871-4021(20)30042-4</article-id><article-id pub-id-type="doi">10.1016/j.dsx.2020.03.002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Clinical considerations for patients with diabetes in times of COVID-19 epidemic</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Gupta</surname><given-names>Ritesh</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Ghosh</surname><given-names>Amerta</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Singh</surname><given-names>Awadhesh Kumar</given-names></name><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Misra</surname><given-names>Anoop</given-names></name><email>anoopmisra@gmail.com</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><aff id="aff1"><label>a</label>Fortis CDOC Hospital, Chirag Enclave, New Delhi, India</aff><aff id="aff2"><label>b</label>GD Hospital and Diabetes Institute, Kolkata, India</aff><aff id="aff3"><label>c</label>National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India</aff><aff id="aff4"><label>d</label>Diabetes Foundation (India), New Delhi, India</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. Fortis CDOC Hospital, Chirag Enclave, New Delhi, India. <email>anoopmisra@gmail.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>10</day><month>3</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub" iso-8601-date="2020-06-01"><season>May-June</season><year>2020</year></pub-date><pub-date pub-type="epub"><day>10</day><month>3</month><year>2020</year></pub-date><volume>14</volume><issue>3</issue><fpage>211</fpage><lpage>212</lpage><permissions><copyright-statement>&#x000a9; 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Diabetes India</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions></article-meta></front><body><sec id="sec1"><label>1</label><title>Background and epidemiology</title><p id="p0010">COVID-19 (Coronavirus Disease-2019), a disease caused by the coronavirus SARS-CoV-2 (Severe Acute Respiratory Syndrome-Coronavirus-2), has emerged as a rapidly spreading communicable disease affecting more than 100 countries across the globe at present. The disease is primarily spread through large respiratory droplets, though the possibility of other routes of transmission cannot be ruled out, as the virus has been found in stool and urine of affected individuals [<xref rid="bib1" ref-type="bibr">1</xref>]. The disease severity has varied from mild self-limiting flu-like illness to fulminant pneumonia, respiratory failure and death. There are regional variations in the mortality rates and these estimates are rapidly changing as more data are becoming available. There were 95,333 confirmed cases of COVID-19 worldwide with a mortality rate of 3.4% according to the situation report of World Health Organisation on March 5, 2020 [<xref rid="bib2" ref-type="bibr">2</xref>]. However, a much lower mortality of 1.4% has been reported in analysis of data of 1099 patients with laboratory-confirmed COVID-19 from 552 hospitals in mainland China [<xref rid="bib3" ref-type="bibr">3</xref>]. Considering that the number of unreported and unconfirmed cases is likely to be much higher than the reported cases, the actual mortality may be less than 1%, which is similar to that of severe seasonal influenza [<xref rid="bib4" ref-type="bibr">4</xref>]. India has 39confirmed cases till 10th March, 2020 and contact surveillance of these cases is going on. The understanding of epidemiological characteristics of this infection is evolving on a daily basis as the disease is spreading to different parts of the globe.</p></sec><sec id="sec2"><label>2</label><title>Diabetes, respiratory infections and COVID19</title><p id="p0015">Individuals with diabetes are at risk of infections, especially influenza and pneumonia. This risk can be reduced, though not completely eliminated, by good glycaemic control. All people with diabetes (above 2 years of age) are recommended pneumococcal and annual influenza vaccinations. Not only this, patients with diabetes have a severe disease when infected with respiratory viruses. Indeed, diabetes was seen as an important risk factor for mortality in patients infected with Pandemic Influenza A 2009 (H1N1), Severe Acute Respiratory Syndrome (SARS) coronavirus and Middle East Respiratory Syndrome-related coronavirus (MERSCoV) [<xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>].</p><p id="p0020">Data about COVID-19 in patients with diabetes is limited at present. Diabetes was present in 42.3% of 26 fatalities due to COVID-19 in Wuhan, China [<xref rid="bib8" ref-type="bibr">8</xref>]. In a study in 140 patients with COVID-19 in Wuhan, China, diabetes was not a risk factor for severe disease course [<xref rid="bib9" ref-type="bibr">9</xref>]. However, another study in 150 patients (68 deaths and 82 recovered patients) in Wuhan showed that the number of co-morbidities to be a significant predictor of mortality [<xref rid="bib10" ref-type="bibr">10</xref>]. Analysis of 11 studies regarding laboratory abnormalities in patients with COVID-19 did not mention raised blood glucose or diabetes as predictor of severe disease [<xref rid="bib11" ref-type="bibr">11</xref>]. Notwithstanding these small series, a report of 72,314 cases of COVID-19 published by Chinese Centre for Disease Control and Prevention showed increased mortality in people with diabetes (2.3%, overall and 7.3%, patients with diabetes) [<xref rid="bib12" ref-type="bibr">12</xref>].</p></sec><sec id="sec3"><label>3</label><title>Measures to prevent COVID-19</title><p id="p0025">Our knowledge about the prevalence of COVID-19 and disease course in people with diabetes will evolve as more detailed analyses are carried out. For now, it is reasonable to assume that people with diabetes are at increased risk of developing infection with SARS-CoV-2. Coexisting heart disease, kidney disease, advanced age and frailty are likely to have further increase in the severity of disease.</p><p id="p0030">Following measures are suggested for prevention of this disease in patients with diabetes:<list list-type="simple" id="olist0010"><list-item id="o0010"><label>A.</label><p id="p0035">Specific Measures in Patients with Diabetes:<list list-type="simple" id="olist0015"><list-item id="o0015"><label>a.</label><p id="p0040">It is important that people with diabetes maintain a good glycaemic control, as it might help in reducing the risk of infection and also the severity. More frequent monitoring of blood glucose levels (with use of self-monitoring blood glucose) is required. Good glycemic control may lessen chances of superadded bacterial pneumonia as well.</p></list-item><list-item id="o0020"><label>b.</label><p id="p0045">Patients with diabetes and co-existing heart disease or kidney disease need special care and attempts should be made to stabilise their cardiac/renal status.</p></list-item><list-item id="o0025"><label>c.</label><p id="p0050">Attention to nutrition and adequate protein intake is important. Any deficiencies of minerals and vitamins need to be taken care of.</p></list-item><list-item id="o0030"><label>d.</label><p id="p0055">Exercise has been shown to improve immunity, though it might be prudent to be careful and avoid crowded places like gymnasia or swimming pools.</p></list-item><list-item id="o0035"><label>e.</label><p id="p0060">It is important to take influenza and pneumonia vaccinations. The latter may decrease chances of secondary bacterial pneumonia after respiratory viral infection, however, data in present viral epidemic is not available.</p></list-item></list>
</p></list-item><list-item id="o0040"><label>B.</label><p id="p0065">General Preventive Measures<list list-type="simple" id="olist0020"><list-item id="o0045"><label>a.</label><p id="p0070">Thorough handwashing with soap and water should be encouraged since it kills the virus. Use of alcohol-based hand rubs is also useful.</p></list-item><list-item id="o0050"><label>b.</label><p id="p0075">There is a need to practise proper respiratory hygiene with covering of mouth and nose with bent elbow or tissue when coughing or sneezing. Touching of mouth, nose and eyes should be avoided.</p></list-item><list-item id="o0055"><label>c.</label><p id="p0080">Contact with an affected person needs to be minimised. Use of recommended face masks is advised if there is a contact with someone with respiratory symptoms.</p></list-item><list-item id="o0060"><label>d.</label><p id="p0085">Non-essential travel to major affected areas should be avoided in order to restrict the spread of infection.</p></list-item></list>
</p></list-item></list>
</p></sec><sec id="sec4"><label>4</label><title>Measures in Patients of diabetes with COVID 19 infection</title><p id="p0090">
<list list-type="simple" id="olist0025"><list-item id="o0065"><label>a.</label><p id="p0095">In case a person with diabetes develops fever, cough, running nose or dyspnoea, the appropriate health authority needs to be notified as testing for this disease is available at selected places only.</p></list-item><list-item id="o0070"><label>b.</label><p id="p0100">The affected person needs to be isolated for 14 days or till the symptoms resolve (whichever is longer).Country-specific guidelines need to be followed.</p></list-item><list-item id="o0075"><label>c.</label><p id="p0105">Majority of patients have a mild disease and can be managed at home. Hydration should be maintained and symptomatic treatment with acetaminophen, steam inhalation etc. can be given.</p></list-item><list-item id="o0080"><label>d.</label><p id="p0110">Patients with type 1 diabetes should measure blood glucose and urinary ketones frequently if fever with hyperglycemia occurs. Frequent changes in dosage and correctional bolus may be required to maintain normoglycemia.</p></list-item><list-item id="o0085"><label>e.</label><p id="p0115">Anti-hyperglycemic agents that can cause volume depletion or hypoglycemia should be avoided. Dosage of oral anti-diabetic drugs may need to be reduced. Patients should follow sick day guidelines and may need more frequent monitoring of blood glucose and drug adjustment.</p></list-item><list-item id="o0090"><label>f.</label><p id="p0120">Hospitalised patients with severe disease need frequent blood glucose monitoring. Oral agents especially metformin and sodium glucose cotransporter-2 inhibitors need to be stopped.</p></list-item><list-item id="o0095"><label>g.</label><p id="p0125">Insulin is the preferred agent for control of hyperglycemia in hospitalised sick patients.</p></list-item></list>
</p></sec><sec id="sec5"><label>5</label><title>Unproven therapies and future directions</title><p id="p0130">In the absence of a specific antiviral drug, anecdotal use of drugs like lopinavir, ritonavir, interferon-1&#x003b2;, RNA polymerase inhibitor remdesivir, and chloroquine has been reported. 2019-nCoV receptor binding site has a strong affinity with angiotensin converting enzyme 2 (ACE2) and inhibitors of the rennin angiotensin system may have a role in treating severe respiratory disease [<xref rid="bib13" ref-type="bibr">13</xref>,<xref rid="bib14" ref-type="bibr">14</xref>]. Zinc nanoparticles were shown to have inhibitory effects on H1N1 viral load, though their effect in COVID-19 is unknown and untested [<xref rid="bib15" ref-type="bibr">15</xref>]. Vitamin C supplementation has some role in prevention of pneumonia and its effect on COVID-19 needs evaluation [<xref rid="bib16" ref-type="bibr">16</xref>]. Efforts to develop a vaccine are underway, which will be a major tool to contain this epidemic [<xref rid="bib17" ref-type="bibr">17</xref>].</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Del Rio</surname><given-names>C.</given-names></name><name><surname>Malani</surname><given-names>P.N.</given-names></name></person-group><article-title>COVID-19-New insights on a rapidly changing epidemic</article-title><source>J&#x000a0;Am Med Assoc</source><year>2020 Feb 28</year><pub-id pub-id-type="doi">10.1001/jama.2020.3072</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="other" id="sref2"><article-title>Coronavirus disease 2019 (COVID-19) situation report &#x02013; 45</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200305-sitrep-45-covid-19.pdf?sfvrsn=ed2ba78b_2" id="intref0010">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200305-sitrep-45-covid-19.pdf?sfvrsn=ed2ba78b_2</ext-link></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.J.</given-names></name><name><surname>Ni</surname><given-names>Z.Y.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>W.H.</given-names></name><name><surname>Ou</surname><given-names>C.Q.</given-names></name><name><surname>He</surname><given-names>J.X.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Shan</surname><given-names>H.</given-names></name><name><surname>Lei</surname><given-names>C.L.</given-names></name><name><surname>Hui</surname><given-names>D.S.C.</given-names></name><name><surname>Du</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>L.J.</given-names></name><name><surname>Zeng</surname><given-names>G.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><name><surname>Chen</surname><given-names>R.C.</given-names></name><name><surname>Tang</surname><given-names>C.L.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Chen</surname><given-names>P.Y.</given-names></name><name><surname>Xiang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>S.Y.</given-names></name><name><surname>Wang</surname><given-names>J.L.</given-names></name><name><surname>Liang</surname><given-names>Z.J.</given-names></name><name><surname>Peng</surname><given-names>Y.X.</given-names></name><name><surname>Wei</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>Y.H.</given-names></name><name><surname>Peng</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>J.M.</given-names></name><name><surname>Liu</surname><given-names>J.Y.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Zheng</surname><given-names>Z.J.</given-names></name><name><surname>Qiu</surname><given-names>S.Q.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Ye</surname><given-names>C.J.</given-names></name><name><surname>Zhu</surname><given-names>S.Y.</given-names></name><name><surname>Zhong</surname><given-names>N.S.</given-names></name></person-group><article-title>China medical treatment expert group for covid-19. Clinical characteristics of coronavirus disease 2019 in China</article-title><source>N&#x000a0;Engl J Med</source><year>2020 Feb 28</year><pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Fauci</surname><given-names>A.S.</given-names></name><name><surname>Lane</surname><given-names>H.C.</given-names></name><name><surname>Redfield</surname><given-names>R.R.</given-names></name></person-group><article-title>Covid-19 - navigating the uncharted</article-title><source>N&#x000a0;Engl J Med</source><year>2020 Feb 28</year><pub-id pub-id-type="doi">10.1056/NEJMe2002387</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.K.1</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Yuan</surname><given-names>M.Y.</given-names></name><name><surname>Yuan</surname><given-names>S.Y.</given-names></name><name><surname>Fu</surname><given-names>H.J.</given-names></name><name><surname>Wu</surname><given-names>B.Y.</given-names></name><name><surname>Sun</surname><given-names>G.Z.</given-names></name><name><surname>Yang</surname><given-names>G.R.</given-names></name><name><surname>Zhang</surname><given-names>X.L.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Xu</surname><given-names>X.P.</given-names></name><name><surname>Chan</surname><given-names>J.C.</given-names></name></person-group><article-title>Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS</article-title><source>Diabet Med</source><volume>23</volume><issue>6</issue><year>2006 Jun</year><fpage>623</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">16759303</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Schoen</surname><given-names>K.</given-names></name><name><surname>Horvat</surname><given-names>N.</given-names></name><name><surname>Guerreiro</surname><given-names>N.F.C.</given-names></name><name><surname>de Castro</surname><given-names>I.</given-names></name><name><surname>de GiassiKS</surname></name></person-group><article-title>Spectrum of clinical and radiographic findings in patients with diagnosis of H1N1 and correlation with clinical severity</article-title><source>BMC Infect Dis</source><volume>19</volume><issue>1</issue><year>2019 Nov 12</year><fpage>964</fpage><pub-id pub-id-type="doi">10.1186/s12879-019-4592-0</pub-id><pub-id pub-id-type="pmid">31718571</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>P.</given-names></name><name><surname>Qu</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>W.</given-names></name><name><surname>Han</surname><given-names>Y.</given-names></name><name><surname>Qin</surname><given-names>C.</given-names></name></person-group><article-title>From SARS to MERS, thrusting coronaviruses into the spotlight</article-title><source>Viruses</source><issue>1</issue><year>2019 Jan 14</year><fpage>11</fpage><comment>E59</comment></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>S.Q.</given-names></name><name><surname>Peng</surname><given-names>H.J.</given-names></name></person-group><article-title>Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China</article-title><source>J&#x000a0;Clin Med</source><issue>2</issue><year>2020 Feb 20</year><fpage>9</fpage><pub-id pub-id-type="doi">10.3390/jcm9020575</pub-id><comment>E575</comment></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.J.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>Y.Y.</given-names></name><name><surname>Yuan</surname><given-names>Y.D.</given-names></name><name><surname>Yang</surname><given-names>Y.B.</given-names></name><name><surname>Yan</surname><given-names>Y.Q.</given-names></name><name><surname>Akdis</surname><given-names>C.A.</given-names></name><name><surname>Gao</surname><given-names>Y.D.</given-names></name></person-group><article-title>Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan</article-title><source>China.Allergy</source><year>2020 Feb 19</year><pub-id pub-id-type="doi">10.1111/all.14238</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name></person-group><article-title>Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China</article-title><source>Intensive Care Med</source><year>2020 Mar 3</year><pub-id pub-id-type="doi">10.1007/s00134-020-05991-x</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Lippi</surname><given-names>G.</given-names></name><name><surname>Plebani</surname><given-names>M.</given-names></name></person-group><article-title>Laboratory abnormalities in patients with COVID-2019 infection</article-title><source>Clin Chem Lab Med</source><year>2020 Mar 3</year><pub-id pub-id-type="doi">10.1515/cclm-2020-0198</pub-id><ext-link ext-link-type="uri" xlink:href="http://pii:/j/cclm.ahead-of-print/cclm-2020-0198/cclm-2020-0198.xml" id="intref0015">pii:/j/cclm.ahead-of-print/cclm-2020-0198/cclm-2020-0198.xml</ext-link></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>McGoogan</surname><given-names>J.M.</given-names></name></person-group><article-title>Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72&#x000a0;314 cases from the Chinese center for disease control and prevention</article-title><source>J&#x000a0;Am Med Assoc</source><year>2020 Feb 24</year><pub-id pub-id-type="doi">10.1001/jama.2020.2648</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>M.L.</given-names></name><name><surname>Yang</surname><given-names>J.M.</given-names></name><name><surname>Sun</surname><given-names>Y.P.</given-names></name><name><surname>Su</surname><given-names>G.H.</given-names></name></person-group><article-title>Inhibitors of RAS might Be a good choice for the therapy of COVID-19 pneumonia</article-title><source>Zhonghua Jiehe He Huxi Zazhi</source><volume>43</volume><year>2020 Feb 16</year><fpage>E014</fpage><pub-id pub-id-type="doi">10.3760/cma.j.issn.1001-0939.2020.0014</pub-id><comment>0</comment><pub-id pub-id-type="pmid">32061198</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Phadke</surname><given-names>M.</given-names></name><name><surname>Saunik</surname><given-names>S.</given-names></name></person-group><article-title>Use of angiotensin receptor blockers such as Telmisartan, Losartsan in nCoV Wuhan Corona Virus infections &#x02013; novel mode of treatment</article-title><source>BMJ</source><volume>368</volume><year>2020</year><comment>m406</comment></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Ghaffari</surname><given-names>H.</given-names></name><name><surname>Tavakoli</surname><given-names>A.</given-names></name><name><surname>Moradi</surname><given-names>A.</given-names></name><name><surname>Tabarraei</surname><given-names>A.</given-names></name><name><surname>Bokharaei-Salim</surname><given-names>F.</given-names></name><name><surname>Zahmatkeshan</surname><given-names>M.</given-names></name><name><surname>Farahmand</surname><given-names>M.</given-names></name><name><surname>Javanmard</surname><given-names>D.</given-names></name><name><surname>Kiani</surname><given-names>S.J.</given-names></name><name><surname>Esghaei</surname><given-names>M.</given-names></name><name><surname>Pirhajati-Mahabadi</surname><given-names>V.</given-names></name><name><surname>Monavari</surname><given-names>S.H.</given-names></name><name><surname>Ataei-Pirkooh</surname><given-names>A.</given-names></name></person-group><article-title>Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine</article-title><source>J&#x000a0;Biomed Sci</source><volume>26</volume><issue>1</issue><year>2019</year><fpage>70</fpage><pub-id pub-id-type="pmid">31500628</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Hemil&#x000e4;</surname><given-names>H.</given-names></name></person-group><article-title>Vitamin C intake and susceptibility to pneumonia</article-title><source>Pediatr Infect Dis J</source><volume>16</volume><issue>9</issue><year>1997 Sep</year><fpage>836</fpage><lpage>837</lpage><pub-id pub-id-type="pmid">9306475</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="other" id="sref17"><article-title>DRAFT landscape of COVID-19 candidate vaccines &#x02014; 18 february 2020. Geneva: World health organization</article-title><ext-link ext-link-type="uri" xlink:href="https://www.who.int/blueprint/priority-diseases/key-action/list-of-candidate-vaccines-developed-against-ncov.pdf.%20opens%20in%20new%20tab" id="intref0020">https://www.who.int/blueprint/priority-diseases/key-action/list-of-candidate-vaccines-developed-against-ncov.pdf. opens in new tab</ext-link></element-citation></ref></ref-list></back></article>